Coming soon · Sunday 25 October · 13:00 CET
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
SymposiumRecording to follow2 CME credits · EACCME
Programme & faculty
The Role of Immune Checkpoint Blockade in SCLC: Achievements & Limitations
Martin ReckGermany
Redefining the Standards: The Era of DLL3 T-Cell Engagers
Solange PetersSwitzerland
Practical Management of DLL3 T-Cell Engagers
Giannis MountziosGreece
The Evolving Algorithm: Sequencing Innovative Strategies
Noemí ReguartSpain
Event details
Main Sponsor
Co-Sponsor
Sponsored Content: This symposium is supported by our partner(s) shown above
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
Continue With
Related Topics
Videos
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
Sep
26
2025
ILCS 2025
SCLC
Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease
34 min
R. Manochakian
Jun
17
2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies
Small Cell Lung Cancer
1h 35 min
G. MountziosJ. SandsS. Peters
Oct
04
2024
ILCS 2024
SCLC
Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies
25 min
S. Liu
Jul
20
2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
O. Gautschi
Nov132026
ILCS 2026
The International Lung Cancer Summit 2026
Learn more about the event
S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
May
04
2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
A. Curioni-Fontecedro
Sep
26
2025
ILCS 2025
Advanced NSCLC
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
32 min
A. Curioni-Fontecedro
Sep
26
2025
ILCS 2025
Immunotherapies
The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC
28 min
A. Filippi
Sep
26
2025
ILCS 2025
Immunotherapies
Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes
36 min
P. Forde
Sep
26
2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Latest Advances in Frontline EGFR+ NSCLC
14 min
A. Curioni-Fontecedro
Sep
26
2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies
Unlocking New Potentials in EGFR-Mutant NSCLC
30 min
A. Passaro
Sep
26
2025
ILCS 2025
ADCs
The ADC Revolution in Lung Cancer: New Targets, New Opportunities
27 min
N. Reguart
Sep
26
2025
ILCS 2025
Targeted Therapies
DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?
31 min
T. Newsom-DavisX. Le
Sep
26
2025
ILCS 2025
Targeted Therapies
Actionable Genomic Alterations – Including HER2 and MET
26 min
S. Saw
Sep
26
2025
ILCS 2025
Targeted Therapies
Targeting EGFR and ALK in NSCLC
26 min
T. John
Sep
26
2025
ILCS 2025
Biomarkers
Cutting-Edge Diagnostic Techniques and Emerging Biomarkers
24 min
M. Ilié
Sep
26
2025
ILCS 2025
Advanced NSCLC
Open Discussion on Patient Cases
22 min
Jul
10
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies
Targeted Therapies in NSCLC
1h 30 min
O. GautschiJ. NaidooN. Girard
Jun
25
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies
Immunotherapies in NSCLC
1h 47 min
P. FordeJ. RemonS. Peters
Articles
Sep
30
2026
RESEARCH
Advanced NSCLCSCLCADCs
Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis
C. Rolfo
Sep
18
2026
CONGRESS
SCLCADCs
Ris-Rez improved OS against topotecan in relapsed SCLC in China
Sep
16
2026
CONGRESS
SCLCTargeted Therapies
Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan
Sep
13
2026
CONGRESS
SCLCADCs
Tam-Peli extends overall survival over topotecan in relapsed SCLC: TAISHAN-302
Sep
13
2026
CONGRESS
SCLC
MAVERICK: MRI surveillance without PCI improves cognitive failure-free survival in SCLC
Sep
13
2026
CONGRESS
Advanced NSCLCSCLCADCs
WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months
Sep
13
2026
CONGRESS
SCLCADCs
ARTEMIS-008: risvutatug rezetecan lifts relapsed-SCLC survival to 18.5 months
Sep
12
2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC
WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response
Sep
10
2026
INDUSTRY NEWS
SCLCImmunotherapies
Tarlatamab added to durvalumab maintenance improved OS in extensive-stage SCLC
Aug
23
2026
RESEARCH
BiomarkersSCLC
SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there
A. Dingemans
Aug
03
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab improved cough, breathlessness and chest pain against chemotherapy in DeLLphi-304
C. RudinG. Mountzios
Jul
14
2026
RESEARCH
Advanced NSCLCSCLCADCs
ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities
R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon
Oct
03
2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies
AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy
A. Calles
Oct
03
2026
RESEARCH
Advanced NSCLCTargeted Therapies
KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials
V. Noronha
Oct
02
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial
X. Le
Oct
02
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC
B. Ricciuti
Oct
01
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study
H. Horinouchi
Oct
01
2026
RESEARCH
Targeted Therapies
RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy
B. RicciutiJ. RemonD. Planchard
Sep
30
2026
RESEARCH
Resectable NSCLC
Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC
S. BerezowskaL. BubendorfP. Hofman
Sep
28
2026
RESEARCH
Resectable NSCLCImmunotherapies
AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1
M. ReckM. Hochmair